Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM
The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.
Bispecifics in Development for the Treatment of R/R MM
Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.
Treatment Options for Patients with Relapsed Multiple Myeloma
Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.
Defining Frail Patients in Multiple Myeloma
Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.
Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.
Data Updates in Transplant Ineligible NDMM
Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.
Selecting Frontline Treatment Regimens for Transplant-Ineligible MM
Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.
Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma
Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.
Assessing Response and Duration of Treatment in Transplant-Eligible NDMM
Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.
Evaluating MRD-Guided Therapy in Patients with NDMM
Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.
Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.
Available Induction Regimen Options for Patients with Transplant-Eligible NDMM
The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.
Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
PFS With Ixazomib + Pomalidomide and Dexamethasone in RRMM: Upcoming Trial Data
Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.
RRMM: Ixazomib Plus Pomalidomide and Dexamethasone
Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.
Importance of MRD in Treating Patients With Multiple Myeloma
Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.
In-Class Transition From Bortezomib to Ixazomib in MM: ASH 2021 Update
Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.
IRd in Multiple Myeloma: Patient-Reported Adherence and Outcomes
Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
Proteasome Inhibition in MM: In-Class Transition From Bortezomib to Ixazomib
Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
TOURMALINE-MM1: Ixazomib Therapy in Relapsed/Refractory MM
Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.
Multiple Myeloma: Real-World Data With Proteasome Inhibitors
Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.
An Overview of Proteasome Inhibitor Therapy in Multiple Myeloma
A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.
Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for Transplant
Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.
Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs
After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.
Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM
Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.
Treatment Options for First-Line Therapy in Transplant-Ineligible MM
In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.
Transplant-Ineligible MM: Treatment After Adequate Response to Therapy
A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.
Transplant-Ineligible Multiple Myeloma: Assessing Response to Therapy
Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.
Multiple Myeloma: Transplant Ineligibility and Goals of Therapy
Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.
